Compare Merck & Co., Inc. (MRK) vs S&P500 ETF (SPY) Price & Performance

Merck & Co., Inc.Trade

S&P500 ETFTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs S&P500 ETF — how do they compare? Merck & Co., Inc. trades at $126.01 (market cap $307.25B), while S&P500 ETF trades at $748.01. The key difference: Merck & Co., Inc. pays a 2.73% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals.

	MRK	SPY
Market Cap	$307.25B	—
Sector	Health	—
52-Week High	$129.52	$759.55
52-Week Low	$77.60	$621.75
Enterprise Value	$350.66B	—
Dividend Yield	2.73%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamentals including a net income margin of 13.59% and ROE of 18.97%. Recent earnings beats and the acquisition of Terns Pharmaceuticals for approximately $6.7 billion highlight strategic growth initiatives. The stock is supported by a consensus analyst price target of $137.30, indicating potential upside from current levels.

The outlook for Merck is positive, driven by robust profitability, strategic acquisitions, and analyst confidence. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the oncology space. Investors should weigh strong cash flow generation against execution risks in integrating recent acquisitions.

S&P500 ETF

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 4 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 1 day agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

SPY

Vanguard's VEA ETF offers low-cost developed market exposure beyond the U.S., balancing diversification and risk.24/7 Wall Street · 6 hours agoNeutral John Hancock Financial Opportunities Fund offers 6.5% growing dividend, beating S&P 500 and financial ETFs.Forbes · 13 hours agoBullish XLK ETF hides high concentration risk in top tech stocks despite low fees.24/7 Wall Street · 1 day agoNeutral View details →

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

About S&P500 ETF

The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.